Objective: To study the effect of exercise on hemodynamic profiles and red blood cell (RBC) concentrations of adenosine-5'-triphosphate (ATP).
Methods: Male Sprague-Dawley (SD) rats (n = 9) were exercised on a treadmill for 15 min at a speed of 10 m/min with a 5% gradient after an hour settling down in a restrainer. Blood samples were collected via an indwelling carotid artery catheter using a ‘Stopping Solution’ from each rat before, during and after exercise. Hemodynamic recordings were collected continuously throughout the experiment. Concentrations of ATP and other purine nucleotides in the RBCs were determined by a validated high-performance liquid chromatography (HPLC) assay. A control group (n = 12) was treated the same way except without the exercise. Data between groups were analyzed by analysis of variance (ANOVA) and Student’s t-test, and differences were considered significant when p < 0.05.
Results: Exercise increased systolic blood pressure (SBP; 141±23 vs. 132±17 mmHg) and heart rate (HR; 420±33 vs. 397±41 bpm), but decreased diastolic blood pressure (DBP; 105±18 vs. 110±14 mmHg). This was followed by a postexercise condition when SBP, DBP, and HR were decreased for the remainder of the experiment. RBC concentrations of ATP and guanosine-5'-triphosphate (GTP) increased significantly during exercise and continued to increase for 5 hours postexercise (1.5±0.75 vs. 0.96 vs. 0.36 mM for ATP; and 0.14±0.061 vs. 0.058±0.030 mM) (p < 0.05).
Conclusion: Exercise increased RBC ATP concentrations in a rodent model, which was correlated with the decrease in BP and HR postexercise.
Antic, S., Lazarevic, G., Velojic, M., Dimic, D. and Stefanovic, V.(2009) Exercise as a therapeutic option in cardiometabolic risk reduction . Med Pregl62(Suppl. 3): 59-65.
2.
Bergfeld, G.R. and Forrester, T. ( 1992) Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovascular Res26: 40-47.
3.
Berne, R. ( 1980) The role of adenosine in the regulation of coronary blood flow. Circ Res47: 807-813.
4.
Burnstock, G. ( 2002) Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol22: 364-373.
5.
Burnstock, G. ( 2009a) Purines and sensory nerves. Handb Exp Pharmacol194: 333-392.
6.
Burnstock, G.(2009b) Purinergic signalling: past, present and future. Braz J Med Biol Res42: 3-8.
7.
Chiao, J.J., Roberts, J.P., Illner, H.P. and Shires, G.T. ( 1987) Permeability of red-cell membrane to adenosine triphosphate (ATP) molecules during hemorrhagic shock. Surgery102: 528-533.
8.
Cohen, M.V. and Downey, J.M. ( 2008) Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol103: 203-215.
9.
Das, M. and Das, D.K. ( 2008) Molecular mechanism of preconditioning. IUBMB Life60: 199-203.
10.
de Jong, J.W., de Jonge, R., Keijzer, E. and Bradamante, S.(2000) The role of adenosine in preconditioning. Pharmacol Ther87: 141-149.
11.
DeJong, J.W. ( 1988) Diagnosis of Ischemic Heart Disease with AMP catabolites , Martinus Nijhoff Publisher: Boston, MA.
12.
Di Francescomarino, S., Sciartilli, A., Di Valerio, V., Di Baldassarre, A. and Gallina, S.(2009) The effect of physical exercise on endothelial function. Sports Med39: 797-812.
13.
Donato, M. and Gelpi, R.J. ( 2003) Adenosine and cardioprotection during reperfusion-an overview . Mol Cell Biochem251: 153-159.
14.
Duthie, G., Beattie, J., Arthur, J., Franklin, M., Morrice, P. and James, W. ( 1994) Blood antioxidants and indices of lipid peroxidation in subjects with angina pectoris. Nutrition10: 313-316.
15.
Ellsworth, M.L. ( 2000) The red blood cell as an oxygen sensor: what is the evidence ? Acta Physiol Scand168: 551-559.
16.
Ely, S.W. and Berne, R.M. ( 1992) Protective effects of adenosine in myocardial ischemia . Circulation85: 893-904.
17.
Franco, M., Perez-Mendez, O. and Martinez, F.(2009) Interaction of intrarenal adenosine and angiotensin II in kidney vascular resistance. Curr Opin Nephrol Hypertens18: 63-67.
18.
Funahashi, M. ( 2003) Effects of ischemic preconditioning on myocardial protective on cardiac surgery: possibility of ischemic preconditioning and adenosine administration. Ann Thorac Cardiovasc Surg9: 307-313.
19.
Funaya, H., Kitakaze, M., Node, K., Minamino, T., Komamura, K. and Hori, M. ( 1997) Plasma adenosine levels increase in patients with chronic heart failure. Circulation95: 1363-1365.
20.
Gerlach, E., Becker, B.F. and Nees, S. ( 1987) Formation of adenosine by vascular endothelium: a homeostatic and antithrombogenic mechanism?, In: Gerlach, E. and Becker, B.F. (eds). The Topic and Perspectives in Adenosine Research, Springer-Verlag : New York, NY, pp 309-320.
21.
Ingwall, J.S. ( 2009) Energy metabolism in heart failure and remodelling. Cardiovasc Res81: 412-419.
22.
Jensen, F.B. ( 2009) The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. J Exp Biol212: 3387-3393.
23.
Kavazis, A.N. ( 2009) Exercise preconditioning of the myocardium. Sports Med39: 923-935.
24.
Kenney, M. and Seals, D. ( 1993) Postexercise hypotension: Key features, mechanisms, and clinical significance. Hypertension22: 653-664.
25.
Kitakaze, M., Minamino, T., Node, K., Koretsune, Y., Komamura, K., Funaya, H. et al. (1998) Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drugs Ther12: 307-309.
26.
Klein, L.C., K Yeung, P. and Berman, J.N. ( 2009) Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. Biomarkers14: 554-559.
27.
Leonelli, M., Torrao, A.S. and Britto, L.R. ( 2009) Unconventional neurotransmitters, neurodegeneration and neuroprotection. Braz J Med Biol Res42: 68-75.
28.
Linden, J. ( 2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol41: 775-787.
29.
McCallion, K., Harkin, D.W. and Gardiner, K.R. ( 2004) Role of adenosine in immunomodulation: review of the literature . Crit Care Med32: 273-277.
30.
Moens, A.L., Claeys, M.J., Timmermans, J.P. and Vrints, C.J. ( 2005) Myocardial ischemia/reperfusioninjury, a clinical view on a complex pathophysiological process. Int J Cardiol100: 179-190.
31.
Obata, T. ( 2002) Adenosine production and its role in protection against ischemic and reperfusion injury of the myocardium. Nippon Yakurigaku Zasshi119: 273-279.
32.
Olsson, R. and Pearson, J. ( 1990) Cardiovascular purinoceptors. Physiol Rev70: 761-845.
33.
Oxhorn, B.C., Cheek, D.J. and Buxton, I.L. ( 2000) Role of nucleotides and nucleosides in the regulation of cardiac blood flow. AACN Clin Issues11: 241-251.
34.
Pescatello, L.S., Franklin, B.A., Fagard, R., Farquhar, W.B., Kelley, G.A. and Ray, C.A. ( 2004) American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc36: 533-553.
35.
Porkka-Heiskanen, T., Kalinchuk, A., Alanko, L., Urrila, A. and Stenberg, D. ( 2003) Adenosine, energy metabolism, and sleep. Sci World J3: 790-798.
36.
Ralevic, V. ( 2009) Purines as neurotransmitters and neuromodulators in blood vessels. Curr Vasc Pharmacol7: 3-14.
37.
Roine, E., Roine, R.P., Rasanen, P., Vuori, I., Sintonen, H. and Saarto, T.(2009) Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: a systematic literature review. Int J Technol Assess Health Care25: 427-454.
38.
Round, S., Hsieh, L. and Agarwal, K. ( 1994) Effects of endotoxin injury on endothelial cell adenosine metabolism. J Lab Clin Med123: 309-317.
39.
Shiode, N., Kato, M., Nakayama, K., Shinohara, K., Kurokawa, J., Yamagata, T. et al. (1998) Effect of adenosine triphosphate on human coronary circulation. Intern Med37: 818-825.
40.
Sollevi, A. ( 1986) Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol27: 319-349.
41.
Tune, J.D., Richmond, K.N., Gorman, M.W. and Feigl, E.O. ( 2002) Control of coronary blood flow during exercise. Exp Biol Med (Maywood) 227: 238-250.
42.
Tykarski, A., Gluszek, J. and Banaszak, F. ( 1993) Value of oxypurines and uric acid in plasma, renal excretion of oxypurines and uric acid as well as plasma adenosine deaminase and AMP deaminase activity with essential hypertension (in Polish). Pol Arch Med Wewn89: 223-229.
43.
Watts, J.A. ( 1986) Protection of ischemic hearts by Ca2+ antagonists. J Mol Cell Cardiol18: 71-75.
44.
Yeung, P., Buckley, S., Hung, O., Pollak, P., Barclay, K., Feng, J. et al. (1997) Effect of diltiazem on plasma concentrations of oxypurines and uric acid. Therap Drug Monit19: 286-291.
45.
Yeung, P., Dauphinee, J., Simonson, K. and Gouzoules, T. ( 2009) RBC concentrations of ATP as potential in vivo biomarkers for cardiovascular safety of anti-hypertensive agents in rats. Clin Pharmacol Ther85(Suppl. 1): S70.
46.
Yeung, P., Ding, L. and Casley, W. ( 2008) HPLC assay with UV detection for determination of RBC purine nucleotides concentrations and application for biomarker study in vivo . J Pharm Biomed Anal47: 377-382.
47.
Yeung, P. and Feng, J. ( 1998) Potential surrogate markers for pharmacodynamics of diltiazem: RBC concentrations of adenosine and adenine nucleotides. Pharm Sci Suppl1: S329.
48.
Yeung, P., Feng, J. and Fice, D. ( 2006) Exercise hemodynamic and neurohormone responses as sensitive biomarkers for diltiazem in rats. J Pharm Pharmaceut Sci9: 245-251.
49.
Yeung, P., Mosher, S., Li, R., Farmer, P., Klassen, G., Pollak, P. et al. (1993) Erythrocyte adenosine transport: A rapid screening test for cardiovascular drugs. J Pharmacol Meth30: 163-167.
50.
Yeung, P., Stadnyk, A., Pollak, P. and Pinto, D. ( 2005) Biomarkers for anti-ischemic drugs. Biomarkers World Congress, Philadelphia, PA.
51.
Yeung, P.K.F., Mosher, S.J., MacRae, D.A. and Klassen, G.A. ( 1991) Effect of diltiazem and its metabolites on the uptake of adenosine in blood: An in-vitro investigation. J Pharm Pharmacol43: 685-689.
